Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02178722 · ClinicalTrials.gov registry record · Phase 1
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
A Phase 1 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 444
- Enrollment target
NCT02178722: Completed Phase 1 study, sponsored by Incyte Corporation.
NCT02178722 is a Phase 1 study that has completed, run by Incyte Corporation. The registered enrollment target is 444 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (640% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02178722, a Phase 1 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 444 participants
- Enrollment target
Study Summary
The purpose of this study was to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in participants with certain cancers. This study was conducted in 2 phases, Phase 1 and Phase 2.
Primary Outcome
An adverse event is defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occur after a participant provides informed consent. A TEAE is any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug. Serious adverse event (SAE) is defined as an event that meets 1 of the following criteria: is fatal or life threatening, results in persistent or significant disability
Interventions
- DRUG MK-3475
- DRUG INCB024360
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 444 participants |
| Start Date | 2014-07-17 |
| Est. Completion | 2020-11-06 |
| Phase | Phase 1 |
What the finished NCT02178722 record still lists
NCT02178722 is an interventional study that assigns participants to a tested intervention. The registered 444 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (640% higher).
The record links to 0 conditions, and to 2 interventions - of which MK-3475 is the first listed.
NCT02178722 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02178722 about?
NCT02178722 is a clinical study titled "Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers". The purpose of this study was to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in participants with certain cancers. This study was conducted in 2 phases, Phase 1 and Phase 2.
What is the current status of trial NCT02178722?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 444 participants. The study started on 2014-07-17. Estimated completion is 2020-11-06.
What interventions are being tested in trial NCT02178722?
The interventions under investigation include: MK-3475 (DRUG), INCB024360 (DRUG).
Who is sponsoring clinical trial NCT02178722?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02178722's enrollment target sits among peer trials
444 59th of 2000 higher than 1,942 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06348394 · 444 participants · NA
Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion
- NCT06700343 · 444 participants · Phase 3
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
- NCT01280994 · 445 participants · Phase 2
Hyperpolarized 129Xe MRI for Imaging Pulmonary Function
- NCT03504800 · 445 participants
OCT in Diagnosis of Irregular Corneas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI